Dernières nouvelles pour CEL-SCI (AMEX:CVM) Stock

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDSX

HLVX

HSCS

INTS

MTVA

ONMD

OPRX

PTPI

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 2412.3% to $5.12 during Tuesday's regular session. The company's market cap stands at $466.1 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 42.47% to $1.61. The company's market cap stands at $4.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 23.28% to $0.28. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 22.5% to $431.22. The market value of their outstanding shares is at $5.6 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 18.79% to $1.68. The market value of their outstanding shares is at $307.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares increased by 17.2% to $1.35. The company's market cap stands at $53.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 31.1% to $7.65 during Tuesday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 17.74% to $8.88. The company's market cap stands at $243.0 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 15.14% to $0.28. The company's market cap stands at $8.1 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 13.64% to $0.01. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.62% to $7.38. The company's market cap stands at $629.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 11.85% to $5.25. The company's market cap stands at $285.3 million. The company's, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

AVXL

BIAF

DBVT

EKSO

EYEN

PLRZ

PTIX

TELA

12 Health Care Stocks Moving In Tuesday's Intraday Session

CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) announced today that during its annual Shareholder's Meeting on May 19, 2025, a combination was authorized for its outstanding shares of common stock. On May 19, 2025, the Board of Directors approved a 1 for 30 combination of common stock. CEL-SCI expects the combination to be implemented on May 20, 2025. When the market opens on May 20, 2025, the common stock will trade under a new CUSIP number 150837 706, but the Company's ticker symbol, CVM, will remain unchanged.
When the combination of stock becomes effective, every 30 shares of common stock will be converted into 1 share of common stock. The combination of common stock will not eliminate any shareholders of record since any fractional share resulting from the combination of common stock will be rounded to the nearest whole share. The exercise price of all outstanding warrants and options, as well as the shares issuable upon the exercise of the outstanding warrants and options, will also be proportionately adjusted.

News

CEL-SCI Corp. Board Approves 1-For-30 Stock Combination, Effective May 20, 2025

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.08) per share. This is a 42.86 percent increase over losses of $(0.14) per share from the same period last year.

Earnings

CEL-SCI Q2 EPS $(0.08) Up From $(0.14) YoY

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 65.3% to $1.67 during Friday's after-market session. The market value of their outstanding shares is at $66.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 9.35% to $1.67. The market value of their outstanding shares is at $3.2 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 7.45% to $0.27. The market value of their outstanding shares is at $22.6 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares moved upwards by 7.08% to $2.87. The market value of their outstanding shares is at $13.1 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 6.66% to $1.28. The company's market cap stands at $23.6 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock moved upwards by 6.63% to $31.48. The market value of their outstanding shares is at $867.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 24.2% to $0.39 during Friday's after-market session. The company's market cap stands at $9.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 15.75% to $0.63. The market value of their outstanding shares is at $7.2 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 12.09% to $1.6. The company's market cap stands at $21.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock declined by 10.86% to $3.04. The company's market cap stands at $11.3 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 8.63% to $0.74. The market value of their outstanding shares is at $3.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 7.4% to $0.6. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCDA

BIVI

BLRX

LENZ

PALI

PSTV

RNAZ

THAR

12 Health Care Stocks Moving In Friday's After-Market Session

Biotech

General

CEL-SCI Met With Saudi Food And Drug Authority, Says Is Preparing To Submit A Regulatory Filing For The Approval Of Multikine As A Neoadjuvant Treatment Of Newly Diagnosed Previously Untreated Locally Advanced Head And Neck Cancer

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BFRG

IMAB

IRWD

MTSR

RSLS

STSS

THRD

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares rose 86.6% to $9.52 during Friday's regular session. The market value of their outstanding shares is at $15.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock moved upwards by 85.15% to $2.37. The company's market cap stands at $5.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares rose 35.78% to $15.14. The company's market cap stands at $543.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 35.02% to $38.13. The company's market cap stands at $496.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 34.42% to $0.02. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 27.88% to $0.27. The company's market cap stands at $22.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 53.3% to $2.31 during Friday's regular session. The company's market cap stands at $5.6 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.04% to $0.24. The market value of their outstanding shares is at $6.1 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares declined by 29.45% to $2.76. The market value of their outstanding shares is at $143.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock fell 22.96% to $1.68. The market value of their outstanding shares is at $3.0 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock declined by 21.52% to $0.22. The company's market cap stands at $1.3 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares declined by 15.96% to $0.48. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBLL

LUCY

MSPR

ONVO

PRTG

YCBD

12 Health Care Stocks Moving In Friday's Intraday Session

Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival
A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=8529d78500a48ee3a0fee230cd3462e9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1535610825000789%3Fvia%253Dihub&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=Cancer+Cell&amp;index=2&amp;md5=a6109e5ec0a40224cd7c3f761761be2b">Cancer Cell</a> (2025) provides support for CEL-SCI's approach aimed at seeking early regulatory approval for Multikine&#x2A; (Leukocyte Interleukin, Injection) as a neoadjuvant in the treatment of newly diagnosed previously untreated locally advanced head and neck cancer based on early tumor responses.
The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The study in Cancer Cell, which had 41 evaluable patients, gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer.

CEL-SCI Announces Study Published In 'Cancer Cell' Confirms Pre-Surgical Tumor Response In Head And Neck Cancer Patients Treated With Its  Multikine Improves Overall Survival, Supporting Early Regulatory Approval As A Neoadjuvant Treatment For Locally Advanced Head And Neck Cancer

CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'

Shares of Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial results and <a href="https://www.benzinga.com/quote/HROW/earnings">issued 2025 revenue guidance</a>.
Harrow shares jumped 23.1% to $28.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 45.7% to $26.96 in pre-market trading after jumping over 46% on Monday.</li>
<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) rose 30.4% to $0.7985 in pre-market trading. Bon Natural Life shares dipped 57% on Monday after the company announced the pricing of a $12 million offering of 8,333,332 shares at $1.44/share.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) gained 19.2% to $0.4774 in pre-market trading following a 10% surge on Monday.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) gained 17.8% to $1.39 in pre-market trading after jumping 7% on Monday.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) gained 15% to $1.46 in pre-market after gaining 4% on Monday.</li>
<li>Key Tronic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) gained 14.2% to $3.05 in pre-market trading.</li>
<li>FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) rose 11% to $10.12 following fourth-quarter results.</li>
<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) rose 9.3% to $14.10 in pre-market trading after gaining 3% on Monday.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 6.3% to $4.73 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 40.3% to $0.5250 in pre-market trading.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) fell 29.4% to $9.05 in pre-market trading after gaining 7% on Monday.</li>
<li>Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) dipped 25.8% to $0.95 in pre-market trading following fourth-quarter results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) declined 24.3% to $0.1280 in pre-market trading.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) fell 24.1% to $0.0802 in pre-market trading after dipping over 6% on Monday.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares tumbled 18.5% to $1.31 in pre-market trading. AirNet Technology shares jumped 98% on Monday after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 13.1% to $0.2469 in pre-market trading. CEL-SCI announced the pricing of $2.56 million best-efforts offering of 16 million shares of common stock.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell 6.8% to $10.70 in today's pre-market trading following a fourth-quarter sales miss.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) fell 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

Offerings

CEL-SCI Announces Pricing Of $2.56M Best-Efforts Offering Of 16M Shares Of Common Stock

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares increased by 107.6% to $5.19 during Monday's pre-market session. The company's market cap stands at $7.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 39.89% to $1.08. The company's market cap stands at $1.0 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 19.85% to $1.63. The company's market cap stands at $258.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares moved upwards by 19.23% to $3.1. The company's market cap stands at $340.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares increased by 17.47% to $4.1. The market value of their outstanding shares is at $19.8 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 14.63% to $0.35. The market value of their outstanding shares is at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares decreased by 25.0% to $2.55 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock decreased by 22.29% to $0.55. The market value of their outstanding shares is at $41.1 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) shares fell 14.9% to $57.75. The market value of their outstanding shares is at $11.1 billion. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 12.55% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) shares declined by 11.65% to $9.71. The company's market cap stands at $425.0 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 9.46% to $0.34. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ANNX

CAPS

CNTX

INCY

MAZE

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo&#xAE;) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1
Multikine&#x2A; is uniquely positioned in the field as the only oncology drug used as a neoadjuvant that has demonstrated overall survival benefit in head and neck cancer patients whose tumors express low levels of PD-L1
Multikine aims to address a major treatment gap for head and neck cancer patients where about 70% have low PD-L1 expression, in its upcoming confirmatory Registration Trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54223970&amp;newsitemid=20250314970798&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=0ce157001ccda3a5a8e3d1caba8cd8a9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a third-party study published on March 6, 2025 in JAMA Oncology titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial" provided data that support Multikine's use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression in its upcoming confirmatory head and neck cancer Registration Trial.

CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized Clinical Trial" Provided Data That Support Multikine's Use As A Neoadjuvant Treatment In Patients With Tumors Having Low PD-L1

Cel-Sci shares are trading higher after the company announced it is in the final stages of its 212-patient confirmatory registration study of Multikine.

CEL-SCI Announces Final Stages For 212-Patient Confirmatory Registration Study Of Multikine In Advanced Head And Neck Cancer To Confirm Phase 3 Efficacy And Safety Results

CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.
"CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of data from the largest Phase 3 head and neck cancer study ever performed, with statistically significant evidence that our drug can successfully fight cancer and extend lives in head and neck cancer," stated CEL-SCI CEO, Geert Kersten. "We hope to deliver a new standard of care to patients while substantially transforming our company's valuation to reflect what we believe to be the intrinsic value of our cancer drug. The statistical analysis shows that our very soon to be initiated small confirmatory Registration Study has a very high chance of success and we will have indications of efficacy as early as 2026. Should the pre-surgical tumor responses mirror what we saw in the Phase 3 data, we believe we will be on the path for accelerated and/or conditional approval for Multikine next year."

CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.75 percent increase over losses of $(0.16) per share from the same period last year.

Earnings Beats

CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.2% to $2.71 during Monday's pre-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock moved upwards by 57.47% to $0.31. The market value of their outstanding shares is at $10.2 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 42.43% to $0.53. The company's market cap stands at $29.1 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares rose 39.39% to $4.6. The market value of their outstanding shares is at $8.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 17.64% to $1.8. The company's market cap stands at $7.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 15.29% to $0.63. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares declined by 40.0% to $8.06 during Monday's pre-market session. The company's market cap stands at $24.3 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock decreased by 29.97% to $0.42. The company's market cap stands at $26.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.64% to $0.38. The company's market cap stands at $27.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 12.48% to $3.93. The company's market cap stands at $203.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock fell 10.66% to $0.53. The company's market cap stands at $314.9 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock declined by 9.91% to $0.19. The market value of their outstanding shares is at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CPHI

MRNS

OTRK

QNRX

SENS

TRAW

VINC

XAIR

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.7% on Monday.
The Dow traded down 0.67% to 42,702.02 while the NASDAQ fell 0.73% to 19,578.50. The S&amp;P 500 also fell, dropping, 0.72% to 5,928.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares rose by 0.2% on Monday.
In trading on Monday, consumer discretionary shares dipped by 1.2%.
Top Headline
U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 5% to $6.69. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 12% to $9.27. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 7% to $14.48. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertical Aerospace Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares dropped 15% to $13.20. The company recently announced it has finalized an investment agreement for up to $50 million in new funding.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 41% to $7.92. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 31% to $0.42. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded down 0.6% at $2,616.00.
Silver traded down 2% to $29.385 on Monday, while copper fell 0.8% to $4.0880.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.46%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.57%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 fell 0.35%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose six points to a reading of 3.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CTKB

EVTL

HSAI

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

Press Releases

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Small Cap

Opinion

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Comments

CEL-SCI

Actualités

Dernières nouvelles pour CEL-SCI (AMEX:CVM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL